Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

DIABETES

SGLT2 inhibitors may prevent diabetes

Dapagliflozin reduces the risk of new-onset diabetes mellitus, according to results from a pre-specified pooled analysis of the DAPA-CKD and DAPA-HF trials. The study adds to the growing list of sodium–glucose co-transporter 2 inhibitor benefits and raises the possibility of an expanded target patient population.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Effect of SGLT2 inhibitors on the risk of a new-onset diagnosis of diabetes in people with prediabetes.

References

  1. Nomura, S. et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53, 6355–6360 (2010).

    CAS  Article  Google Scholar 

  2. Herrington, W. G. et al. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur. J. Heart Fail. 23, 1260–1275 (2021).

    CAS  Article  Google Scholar 

  3. Rossing, P. et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 10, 24–34 (2022).

    CAS  Article  Google Scholar 

  4. Inzucchi, S. E. et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care 44, 586–594 (2021).

    CAS  Article  Google Scholar 

  5. Steven, S. et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13, 370–385 (2017).

    CAS  Article  Google Scholar 

  6. Folz, R. & Laiteerapong, N. The legacy effect in diabetes: are there long-term benefits? Diabetologia 64, 2131–2137 (2021).

    Article  Google Scholar 

  7. Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).

    CAS  Article  Google Scholar 

  8. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).

    CAS  Article  Google Scholar 

  9. International Diabetes Federation. IDF Diabetes Atlas 10th edn (International Diabetes Federation, 2021); https://www.diabetesatlas.org

  10. Cai, X. et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. Br. Med. J. 370, m2297 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

D.V.O. receives support through an Australian Government Research Training Program Scholarship and an NHMRC Clinical Trials Centre Postgraduate Research Scholarship. M.J.J. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Meg J. Jardine.

Ethics declarations

Competing interests

M.J.J. is responsible for research projects that have received funding from CSL, Dimerix, Eli Lilly and MSD and has received advisory, steering committee and/or speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL, Janssen, Merck, MSD, Roche and Vifor (all consultancy fees or honoraria are paid to her institution). D.V.O. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

O’Hara, D.V., Jardine, M.J. SGLT2 inhibitors may prevent diabetes. Nat Rev Nephrol 18, 203–204 (2022). https://doi.org/10.1038/s41581-022-00541-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-022-00541-8

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing